Compvide announced a strategic collaboration with OpZira to support growth and accelerate development of the CIMED™ platform.

Compvide, Inc., a biotechnology company pioneering functional complement intelligence through innovative diagnostics and immune-response monitoring, today announced a strategic collaboration with OpZi ...

A patient with type 1 diabetes received genetically modified allogeneic islets and no immunosuppression. Results obtained ...

Aethlon Medical (Nasdaq: AEMD) reports the second cohort of its Australian oncology feasibility study showed directional ...

A new review was published in Volume 13 of Oncoscience on May 22, 2026, titled "Adaptor proteins regulating tumor-associated macrophage polarization during cancer progression." ...

Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a ...

Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical ...

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing s ...

A 2026 UCLA study found creatine may energize cancer-fighting immune cells. Explore the full science behind creatine health ...

Patients with end-stage renal disease who have no access to a human donor kidney are now receiving gene-edited pig kidneys in ...

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with ...

Non-drug therapies like pacing, CBT, warm-water exercise and cryotherapy may help manage fibromyalgia and chronic fatigue ...